Christopher Nortcliffe

Mass Spectrometry Manager @Sterling Pharma Solutions

Deeside, GB

We provide high resolution mass spectrometry to complement ADC, biopharmaceutical and API discovery and development.Our team of specialists utilise mass spectrometry to assist in the discovery and development of ADCs for in-process, release and stability purposes. Our Deeside facility is specially designed to handle highly cytotoxic materials, this combined with our extensive background in protein conjugate development provides us with the capacity and capability required for even the most complex analytical requirement. Mass spectrometry services for biomolecules:• Intact characterisation on proteins and protein drug conjugates• Native Mass Spectrometry • Intact characterisation and DAR of cysteine and lysine linked ADC’s• Subunit characterisation of proteins and ADC’s• Characterisation of next-generation biologics (nanobodies, bispecific, fusion proteins etc)• Peptide mapping via enzymatic digestion of ADCs and proteins • Disulfide bond confirmation• Plasma stability of ADC’sMass spectrometry services for small molecules:• Accurate mass confirmation• Structural characterisation via fragmentation• Impurity profiling with LC/UV/MS

University of Glasgow

MRes, Proteomics and Cell Technology

The University of Edinburgh

MChem, Medicinal and Biological Chemistry

The University of Manchester

Doctor of Philosophy - PhD, Biophysical Chemistry: Ion Mobility Mass Spectrometry